AB052. A multicenter prospective exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma
Preoperative neoBev was confirmed a safe procedure. mOS in the present cohort was not significantly prolonged. Early tumor volume regression on T1CE but not FLAIR after neoBev therapy has a significant prognostic indicator for mOS in nGB.
Authors
- Hikaru Sasaki (ORCID: https://orcid.org/0000-0001-7380-1931)
- Ryota Tamura (ORCID: https://orcid.org/0000-0002-8637-901X)
- Yuichi Murayama (ORCID: https://orcid.org/0000-0003-3490-385X)
- Toshihide Tanaka (ORCID: https://orcid.org/0000-0002-6474-6317)
- Jun Takei (ORCID: https://orcid.org/0000-0003-3879-9252)
- Keisuke Miyake (ORCID: https://orcid.org/0000-0002-7611-6486)
- Yohei Yamamoto (ORCID: https://orcid.org/0000-0001-9838-3211)
- Yasuharu Akasaki (ORCID: https://orcid.org/0000-0001-8015-084X)
Institutions
- Jikei University School of Medicine (JP)
- Kagawa University (JP)
- Keio University (JP)
- Tokyo Dental College Ichikawa General Hospital (JP)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/cco-24-ab052
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00